“…Relevantly, many drugs routinely used for chronic pain management have been shown to decrease IL-6 levels, especially lidocaine IV, cannabinoids, and (indirectly) anticonvulsants. [17][18][19][20][21][22][23][24][25][26] According to the 2017 National Health Survey in Spain, [27] low back pain and osteoarthritis are the second and third most common health problems in Spain, affecting 18.5% and 17.5%, respectively, of the population. Given this high prevalence, the potential effects of drugs used to treat these and other comorbidities in patients with COVID-19 may be particularly relevant for individuals receiving medical treatment for chronic pain, which include NSAIDs, paracetamol, metamizole, corticosteroids, opioids, anticonvulsants, antidepressants, lidocaine, ketamine, cannabinoids, and naltrexone.…”